Personalized gene-targeting drug for one person with Charcot-Marie-Tooth disease type 2D
Tests a custom antisense drug in one person with Charcot-Marie-Tooth disease type 2D.
Key facts
- Who runs it
- n-Lorem Foundation
- Where
- Houston, United StatesSee the site
- Trial code
- Registry title
- Personalized Antisense Oligonucleotide for A Single Participant With GARS1 Gene Mutation Associated With Charcot-Marie-Tooth Disease Type 2D (CMT2D)
- Status
- Enrolling by invitation
- Phase
- Phase 1/2
- People taking part
- 1 person, planned
- Started
- 27 Oct 2025
- Expected to end
- Oct 2027
- Type of study
- Interventional
- Treatments tested
- nL-GARS1-001
- Record updated
- 10 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for one single participant with Charcot-Marie-Tooth disease type 2D (CMT2D) caused by a change in the GARS1 gene. The participant gets a personal experimental drug called nL-GARS1-001.
- Age
- 13 Years and older
- Sex
- Female
- Disease stage
- Charcot-Marie-Tooth disease type 2D (CMT2D) due to a harmful, new (de novo) deletion in GARS1.
- Biomarker or test result
- A GARS1 gene change confirmed by genetic testing.
Main reasons for not taking part
- Any condition that, in the study doctor's opinion, would stop the participant from completing the study steps.
- Not able to travel to the study site and attend follow-up visits.
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Informed consent/assent provided by the participant (when appropriate), and/or the participant's parent(s) or legally authorized representative(s)
- Ability to travel to the study site and adhere to study-related follow-up examinations and/or procedures and provide access to participant's medical records; Genetically confirmed GARS1 genetic variant
Who cannot take part
- Participant has any condition that, in the opinion of the Site Investigator, would ultimately prevent the completion of study procedures
Where in United States
- UTHealth HoustonHouston, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with Charcot-Marie-Tooth disease type 2D (CMT2D) due to a pathogenic, de novo deletion mutation in GARS1
The group in the trial
- Open LabelTreatment being tested
Treatment: nL-GARS1-001
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open-label Single Center, Single Participant Study of an Experimental Antisense Oligonucleotide Treatment for Charcot-Marie-Tooth Type 2D Due to GARS1 Genetic Mutation
- Plain-language title
- Personalized gene-targeting drug for one person with Charcot-Marie-Tooth disease type 2DGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 10 November 2025